Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | RXRA | P19793 | 13/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 13/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL718521 | 0.91 | LOXL2 (0.42) | GPR119RXRAGRIN1GRIN2BLOXL2 | |
| SCHEMBL720485 | 0.89 | LOXL2 (0.43) | RXRAGRIN1GRIN2BLOXL2CA12 | |
| SCHEMBL722541 | 0.78 | GPR119 (0.48) | GPR119CA12CA1CA2CA9 | |
| SCHEMBL720852 | 0.76 | GPR119 (0.51) | GPR119 | |
| Tert-Butyl Formate SCHEMBL28786710 | 0.72 | LOXL2 (0.44) | GPR119RXRAGRIN1GRIN2BLOXL2 | |
| SCHEMBL4289925 | 0.72 | GPR119 (0.61) | GPR119 | |
| SCHEMBL16242409 | 0.70 | GPR119 (0.46) | GPR119LOXL2 | |
| SCHEMBL720225 | 0.68 | GPR119 (0.44) | GPR119 | |
| SCHEMBL719914 | 0.68 | CA12 (0.42) | GPR119CA12CA1CA2CA9 | |
| SCHEMBL717665 | 0.67 | KMT2A (0.43) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | GPR119 1/4885RXRA 1623/4885GRIN1 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.